Thomas Schuetz
Fundador en COMPASS THERAPEUTICS, INC. .
Fortuna: 10 M $ al 30/04/2024
Cargos activos de Thomas Schuetz
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
COMPASS THERAPEUTICS, INC. | Director/Miembro de la Junta | 01/01/2014 | - |
Director Técnico/Científico/I+D | 09/01/2024 | - | |
Fundador | 01/01/2014 | - | |
Director Ejecutivo | 01/01/2014 | 09/01/2024 | |
Presidente | 01/01/2014 | 15/09/2020 | |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Director/Miembro de la Junta | - | - |
Compass Therapeutics LLC
Compass Therapeutics LLC BiotechnologyHealth Technology Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Director/Miembro de la Junta | 01/01/2014 | - | |
Director Ejecutivo | 01/01/2014 | - | |
Fundador | 01/01/2014 | - | |
Arteaus Therapeutics LLC
Arteaus Therapeutics LLC BiotechnologyHealth Technology Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA. | Director/Miembro de la Junta | - | - |
Historial de carrera de Thomas Schuetz
Antiguos cargos conocidos de Thomas Schuetz.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
AUDENTES THERAPEUTICS, INC. | Director/Miembro de la Junta | 01/07/2013 | 15/01/2020 |
Fundador | 13/11/2012 | 15/01/2020 | |
Independent Dir/Board Member | 01/07/2013 | 15/01/2020 | |
RELYPSA INC | Director/Miembro de la Junta | 01/08/2010 | 01/09/2016 |
Independent Dir/Board Member | 01/08/2010 | 01/09/2016 | |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Director/Miembro de la Junta | 01/01/2007 | 01/01/2012 |
Therion Biologics Corp.
Therion Biologics Corp. Pharmaceuticals: MajorHealth Technology Therion Biologics Corp. developed therapeutic vaccines for cancer patients. The company was founded on May 5, 1991 and was headquartered in Cambridge, MA. | Director Técnico/Científico/I+D | 01/01/2003 | 01/01/2006 |
Olivia Ventures, Inc.
Olivia Ventures, Inc. Financial ConglomeratesFinance Olivia Ventures, Inc. is a blank check company. It acts as a vehicle to investigate and to pursue a business combination. The company was founded on March 20, 2018 and is headquartered in Boca Raton, FL. | Director/Miembro de la Junta | 17/06/2020 | - |
Director Ejecutivo | 17/06/2020 | - | |
Presidente | 17/06/2020 | - | |
░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ ░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░ ░░░░░░░░░░ ░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formación de Thomas Schuetz.
Harvard University | Doctorate Degree |
Harvard Medical School | Doctorate Degree |
Xavier University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 16 |
Canadá | 3 |
Operativa
Director/Board Member | 8 |
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 4 |
Sectorial
Health Technology | 10 |
Finance | 5 |
Consumer Services | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
COMPASS THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 13 |
---|---|
Limulus Management Co. LLC
Limulus Management Co. LLC Investment ManagersFinance Limulus Management Co. LLC is a venture capital firm founded by Lawrence Miller and Paul Howard in 1999. It is headquartered in Newton, Massachusetts. | Finance |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
Therion Biologics Corp.
Therion Biologics Corp. Pharmaceuticals: MajorHealth Technology Therion Biologics Corp. developed therapeutic vaccines for cancer patients. The company was founded on May 5, 1991 and was headquartered in Cambridge, MA. | Health Technology |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Finance |
Gelesis, Inc.
Gelesis, Inc. BiotechnologyHealth Technology Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA. | Health Technology |
Arteaus Therapeutics LLC
Arteaus Therapeutics LLC BiotechnologyHealth Technology Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA. | Health Technology |
Relypsa, Inc.
Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
OrbiMed Advisors LLC
OrbiMed Advisors LLC Investment ManagersFinance OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds. | Finance |
Astellas Gene Therapies, Inc.
Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Compass Therapeutics LLC
Compass Therapeutics LLC BiotechnologyHealth Technology Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA. | Health Technology |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Health Technology |
Olivia Ventures, Inc.
Olivia Ventures, Inc. Financial ConglomeratesFinance Olivia Ventures, Inc. is a blank check company. It acts as a vehicle to investigate and to pursue a business combination. The company was founded on March 20, 2018 and is headquartered in Boca Raton, FL. | Finance |
- Bolsa de valores
- Insiders
- Thomas Schuetz
- Experiencia